CO2023016037A2 - Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos - Google Patents

Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos

Info

Publication number
CO2023016037A2
CO2023016037A2 CONC2023/0016037A CO2023016037A CO2023016037A2 CO 2023016037 A2 CO2023016037 A2 CO 2023016037A2 CO 2023016037 A CO2023016037 A CO 2023016037A CO 2023016037 A2 CO2023016037 A2 CO 2023016037A2
Authority
CO
Colombia
Prior art keywords
antibodies
tigit
methods
molecules
multispecific
Prior art date
Application number
CONC2023/0016037A
Other languages
English (en)
Inventor
Dhan Sidhartha Chand
Zahra Jawad
Olga Ignatovich
Nicola Anne Ramsay
Spencer Campbell
Beth Wensley
Emmanuel Cyrille Pascal Briend
K Mark Bushell
Benjamin Maxime Morin
Veronica Franciszka Ilkow
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of CO2023016037A2 publication Critical patent/CO2023016037A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción proporciona moléculas multiespecíficas que se unen específicamente a CD96 (por ejemplo, CD96 humano) y/o TIGIT (por ejemplo, TIGIT humano) y anticuerpos aislados que se unen específicamente a TIGIT (por ejemplo, TIGIT humano). También se proporcionan composiciones farmacéuticas que comprenden estas moléculas y anticuerpos multiespecíficos, ácidos nucleicos que codifican estas moléculas y anticuerpos multiespecíficos, vectores de expresión y células hospederas para preparar estas moléculas y anticuerpos multiespecíficos, y métodos para tratar a un sujeto mediante el uso de estas moléculas y anticuerpos multiespecíficos.
CONC2023/0016037A 2021-05-04 2023-11-23 Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos CO2023016037A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163201537P 2021-05-04 2021-05-04
PCT/US2022/072099 WO2022236276A2 (en) 2021-05-04 2022-05-04 Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2023016037A2 true CO2023016037A2 (es) 2023-11-30

Family

ID=83933041

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0016037A CO2023016037A2 (es) 2021-05-04 2023-11-23 Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos

Country Status (16)

Country Link
US (2) US11718669B2 (es)
EP (1) EP4333893A2 (es)
JP (1) JP2024516843A (es)
KR (1) KR20240006054A (es)
CN (1) CN117425494A (es)
AR (1) AR125753A1 (es)
AU (1) AU2022271331A1 (es)
BR (1) BR112023022319A2 (es)
CA (1) CA3217289A1 (es)
CL (1) CL2023003244A1 (es)
CO (1) CO2023016037A2 (es)
IL (1) IL308157A (es)
MX (1) MX2023013078A (es)
PE (1) PE20240369A1 (es)
TW (1) TW202304965A (es)
WO (1) WO2022236276A2 (es)

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335552D1 (de) 2002-09-11 2011-02-10 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
EP3683230A1 (en) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
SG10201402815VA (en) 2008-04-09 2014-09-26 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
DK2542590T4 (da) 2010-03-05 2020-07-13 Univ Johns Hopkins Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
US20130287797A1 (en) 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
JP2015520192A (ja) 2012-06-06 2015-07-16 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｈｉｐｐｏ経路を調節する結合剤およびその使用
US9873740B2 (en) 2013-07-16 2018-01-23 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
PL3036258T3 (pl) 2013-08-22 2023-12-11 The Council Of The Queensland Institute Of Medical Research Modulowanie receptora dla leczenia raka i infekcji wirusowych
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
MX2016003617A (es) * 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
EA201790195A1 (ru) 2014-07-16 2017-09-29 Дженентек, Инк. Способы лечения рака с применением ингибиторов tigit и противораковых агентов
CN113583131B (zh) 2014-08-19 2024-09-03 默沙东有限责任公司 抗tigit抗体
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EP3209382B1 (en) 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
RU2017119428A (ru) 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
SG11201705063VA (en) 2014-12-23 2017-07-28 Bristol Myers Squibb Co Antibodies to tigit
BR112017020491A2 (pt) 2015-03-25 2018-07-17 The Regents Of The University Of Michigan composições e métodos para distribuição de agentes de biomacromolécula.
WO2016180781A1 (en) 2015-05-08 2016-11-17 Michele Maio Combination therapy of mesothelioma
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
AU2016303485A1 (en) 2015-07-31 2018-03-01 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017037707A1 (en) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
JP2018531914A (ja) 2015-09-14 2018-11-01 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ＣＤ１５５／ＴＩＧＩＴ経路およびＴＧＦ−βのアンタゴニストを介してがんを処置するための組成物および方法
TWI811892B (zh) 2015-09-25 2023-08-11 美商建南德克公司 抗tigit抗體及使用方法
RU2020124191A (ru) 2015-10-01 2020-08-27 Потенза Терапевтикс, Инк. Анти-tigit антиген-связывающие белки и способы их применения
RU2731202C2 (ru) 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
US10421810B2 (en) 2015-10-09 2019-09-24 Lentigen Technology, Inc. Chimeric antigen receptors and methods of use
US11612426B2 (en) 2016-01-15 2023-03-28 Immunsys, Inc. Immunologic treatment of cancer
CA3014934A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
JP2019519548A (ja) 2016-06-17 2019-07-11 ヴァリアン メディカル システムズ インコーポレイテッド 放射線処置と組み合わせた免疫調節剤
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
DK3347379T5 (da) 2016-08-17 2020-06-15 Compugen Ltd Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
MX2019002925A (es) 2016-09-15 2019-09-05 Idera Pharmaceuticals Inc Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
EP3548071A4 (en) 2016-11-30 2020-07-15 OncoMed Pharmaceuticals, Inc. METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
SG10202103227YA (en) 2017-02-28 2021-04-29 Seattle Genetics Inc Anti-tigit antibodies
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
TWI805582B (zh) * 2017-05-01 2023-06-21 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
MX2019013033A (es) 2017-05-02 2020-02-05 Merck Sharp & Dohme Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US20200407445A1 (en) 2017-07-27 2020-12-31 Iteos Therapeutics Sa Anti-tigit antibodies
TWI803523B (zh) 2017-09-29 2023-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｔｉｇｉｔ抗體、其抗原結合片段及醫藥用途
CN110914304B (zh) 2017-11-10 2022-07-26 江苏恒瑞医药股份有限公司 Cd96抗体、其抗原结合片段及医药用途
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
TW202400654A (zh) * 2017-12-30 2024-01-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
KR20200109313A (ko) 2018-01-15 2020-09-22 난징 레전드 바이오테크 씨오., 엘티디. Tigit에 대한 항체 및 이의 변이체
WO2019152574A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
CA3086936C (en) 2018-02-06 2022-11-29 I-Mab Biopharma Us Limited Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
WO2019165434A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
MX2020008795A (es) 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
JP2022513406A (ja) * 2018-10-31 2022-02-07 デリニア インコーポレイテッド 多価制御性ｔ細胞調節因子
WO2020185739A1 (en) * 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
JP2022539527A (ja) * 2019-06-26 2022-09-12 エーピー バイオサイエンシーズ， インコーポレイテッド Ｔ細胞活性化のための抗体
CA3152027A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
MX2023012707A (es) * 2021-05-04 2023-11-06 Agenus Inc Anticuerpos de la proteina inmunorreceptora de celulas t con dominios ig e itim (anti-tigit) y metodos de uso de estos.

Also Published As

Publication number Publication date
TW202304965A (zh) 2023-02-01
EP4333893A2 (en) 2024-03-13
WO2022236276A2 (en) 2022-11-10
KR20240006054A (ko) 2024-01-12
CN117425494A (zh) 2024-01-19
PE20240369A1 (es) 2024-03-04
MX2023013078A (es) 2023-11-16
CL2023003244A1 (es) 2024-04-19
AU2022271331A1 (en) 2023-10-26
US11718669B2 (en) 2023-08-08
AU2022271331A9 (en) 2023-11-09
BR112023022319A2 (pt) 2024-02-20
IL308157A (en) 2024-01-01
US20240141039A1 (en) 2024-05-02
CA3217289A1 (en) 2022-11-10
US20230014036A1 (en) 2023-01-19
WO2022236276A3 (en) 2023-01-19
AR125753A1 (es) 2023-08-09
JP2024516843A (ja) 2024-04-17

Similar Documents

Publication Publication Date Title
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
AR114275A1 (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
BR112022014667A2 (pt) Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
AR115389A1 (es) Anticuerpo antagonista de cd73
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
AR109276A1 (es) ANTICUERPOS ANTI-hCTLA 4
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
CL2021000028A1 (es) Anticuerpo multiespecifico (divisional de solicitud 937-2020).
BR112017007093A2 (pt) composições e métodos de uso para aumento da resposta imune e terapia do câncer
ECSP22014455A (es) Anticuerpos anti-cd96 y sus métodos de uso
PE20171764A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112015017548A8 (pt) construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica
BR112017023692A2 (pt) moléculas imunoterapêuticas glican-dependentes
UY39416A (es) Moléculas de direccionamiento inmunes multiespecíficas y usos de estas
BR112022011854A2 (pt) Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos